Abstract
Oncogene-driven proliferative signaling in tumor cells requires comprehensive upregulation of cellular energy metabolism and macromolecule syntheses. These alterations are now known to include not only upregulated glycolysis, but also increased fatty acid metabolism, glutaminolysis, deregulated mitochondrial function and more. Many prospective targets for tumor-specific pharmacological modulation of metabolism have therefore been identified. While the prospective drugs do not necessarily show very high antitumor activity by themselves, they may by depriving tumor cells of energy and building blocks for repair and proliferation come to be of major clinical use as potentiators of standard chemotherapeutic drugs and/or radiation. To this end, not only inhibitors of specific enzyme functions are being investigated, but also drugs affecting the complex signaling networks that regulate organismal and cellular energy status. This review provides examples of how modulators of energy metabolism (MEMs) targetting different aspects of tumor cell metabolism have been found to potentiate cancer treatment in vitro and in vivo.
Keywords: Cancer chemotherapy, energy metabolism, potentiation, Oncogene-driven proliferative signaling, glutaminolysis, standard chemotherapeutic drugs (SCDs)
Current Pharmaceutical Biotechnology
Title:Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Volume: 14 Issue: 3
Author(s): Maria C. Shoshan
Affiliation:
Keywords: Cancer chemotherapy, energy metabolism, potentiation, Oncogene-driven proliferative signaling, glutaminolysis, standard chemotherapeutic drugs (SCDs)
Abstract: Oncogene-driven proliferative signaling in tumor cells requires comprehensive upregulation of cellular energy metabolism and macromolecule syntheses. These alterations are now known to include not only upregulated glycolysis, but also increased fatty acid metabolism, glutaminolysis, deregulated mitochondrial function and more. Many prospective targets for tumor-specific pharmacological modulation of metabolism have therefore been identified. While the prospective drugs do not necessarily show very high antitumor activity by themselves, they may by depriving tumor cells of energy and building blocks for repair and proliferation come to be of major clinical use as potentiators of standard chemotherapeutic drugs and/or radiation. To this end, not only inhibitors of specific enzyme functions are being investigated, but also drugs affecting the complex signaling networks that regulate organismal and cellular energy status. This review provides examples of how modulators of energy metabolism (MEMs) targetting different aspects of tumor cell metabolism have been found to potentiate cancer treatment in vitro and in vivo.
Export Options
About this article
Cite this article as:
C. Shoshan Maria, Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism, Current Pharmaceutical Biotechnology 2013; 14 (3) . https://dx.doi.org/10.2174/1389201011314030007
DOI https://dx.doi.org/10.2174/1389201011314030007 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological
Aspects in Treating the COVID-19
Current Molecular Pharmacology The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Mini-Reviews in Medicinal Chemistry Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Transcription Factor CHF1/Hey2 Regulates Specific Pathways in Serum Stimulated Primary Cardiac Myocytes: Implications for Cardiac Hypertrophy
Current Genomics Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety Obesity-Induced Cerebral Hypoperfusion Derived from Endothelial Dysfunction: One of the Risk Factors for Alzheimer's Disease
Current Alzheimer Research Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: An Update
Current Respiratory Medicine Reviews Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Optimal Oxygen Therapy in the Critically Ill Patient with Respiratory Failure
Current Respiratory Medicine Reviews Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Patent Selections:
Recent Patents on Regenerative Medicine The Role of Vitamin D in Atherosclerosis Inflammation Revisited: More a Bystander than a Player?
Current Vascular Pharmacology Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews Biomarkers of Alcohol Consumption in Body Fluids - Possibilities and Limitations of Application in Toxicological Analysis
Current Medicinal Chemistry Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design